SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

The $132.3M raise provides a multi-year cash runway through key Phase 3 readouts. Monitor Q3 2026 for CHAPTER-3 topline data, which is the primary catalyst. The offering was fully subscribed with underwriter option exercise, indicating strong institutional demand despite dilution.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.25
T+0 close · May 11, 2026 · via day close
Latest settled
+10.24%
T+60 · $34.45
Vs SPY
+5.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $31.25entry
  2. T+1 · 6mo ago 0.00%α −0.54% · $31.25
  3. T+5 · 6mo ago −7.81%α −7.89% · $28.81
  4. T+20 · 5mo ago +0.83%α +2.56% · $31.51
  5. T+60 · 3mo ago +10.24%α +5.86% · $34.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise of the underwriters' option. The proceeds provide a significant cash runway for late-stage clinical programs, including the pivotal Phase 3 CHAPTER-3 study for HAE prevention with topline data expected in Q3 2026.

Key Financial Metrics

Deal Value
$132.3M

Key Facts

  • Closed underwritten offering of 4,455,863 ordinary shares at gross proceeds of ~$132.3M
  • Underwriters exercised option in full for an additional 581,199 shares
  • Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acted as joint book-running managers
  • Proceeds will fund late-stage clinical programs including CHAPTER-3 Phase 3 study for HAE prevention
  • Topline data from CHAPTER-3 study anticipated in Q3 2026
  • CREAATE Phase 3 study for AAE-C1INH is ongoing

Financial Impact

$132.3M gross proceeds from offering

cashdilutionshare count

Risk Factors

  • Dilution of ~4.5M shares (approximately 10-15% of pre-offering shares outstanding)
  • Clinical trial risk for CHAPTER-3 and CREAATE studies
  • No revenue-generating products approved yet

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292354

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026